Yuling Li

Q: What is Yuling Li email address?

Email Yuling Li at yuling79@yahoo.com and yuling.li@innoforcepharma.com. This email is the most updated Yuling Li's email found in 2026.

Q: How to contact Yuling Li?

To contact Yuling Li send an email to yuling79@yahoo.com or yuling.li@innoforcepharma.com. (updated on July 27, 2022)

Co-founder and CEO (2018.08-2023.07), President (2023.08 - Present） at Innoforce Pharmaceuticals | United States

About Yuling Li

Yuling Li is a distinguished leader in the biopharmaceutical sector, currently serving as the President of Innoforce Pharmaceuticals after co-founding the company in August 2018 and leading it as CEO until July 2023. Under her stewardship, Innoforce has emerged as a pivotal player in the development and commercialization of Advanced Therapy Medicinal Products (ATMPs) and biologics. Yuling's vision for the company is rooted in fostering partnerships that bridge the pharmaceutical landscapes of the East and West, enhancing innovation and accelerating the delivery of groundbreaking therapies to patients.

Her extensive expertise spans critical aspects of biopharmaceutical Chemistry, Manufacturing, and Controls (CMC), where she has demonstrated exceptional leadership in both strategic and tactical functions. Yuling has been instrumental in establishing Innoforce as a premier contract development and manufacturing organization (CDMO), offering comprehensive services that include GMP manufacturing of mRNA, plasmid DNA, viral vectors, and cell therapies. This end-to-end capability not only streamlines the drug development process but also positions Innoforce as a trusted partner for companies looking to navigate the complexities of biopharmaceutical production.

Yuling's commitment to scientific excellence is complemented by her strong operational leadership, which has enabled Innoforce to successfully manage key projects that drive innovation in drug discovery and development. Her proficiency in cell biology, immunology, and recombinant DNA technology has been crucial in advancing the company's portfolio of therapies. As she continues to lead Innoforce into its next phase of growth, Yuling Li remains dedicated to enhancing the capabilities that empower the biopharmaceutical industry to meet the evolving needs of global health.

Yuling Li Work